

CSD/BSE&NSE/2025-26
December 5, 2025

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001
Scrip Code: 543064

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051
Scrip Symbol: COHANCE

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding appointment of Senior Management Personnel

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015 (“SEBI Listing Regulations”), we hereby inform that the Board of Directors of the Company, based on the recommendations of the Nomination and Remuneration Committee, by way of Circular Resolution passed today, i.e. on December 5, 2025, has,:

- a) approved the appointment of Mr. Gunjan Singh, Business Head – API plus, as Senior Management Personnel of the Company, with effect from December 5, 2025. The brief profile of Mr. Gunjan is annexed with this disclosure;
- b) approved the appointment of Mr. Amrit Singh, Head – Specialty Chemicals, as Senior Management Personnel of the Company, with effect from December 5, 2025. The brief profile of Mr. Amrit is annexed with this disclosure; and
- c) approved the appointment of Mr. Ravinatha Shetty, Platform Chief Operating Officer, as Senior Management Personnel of the Company, with effect from December 5, 2025. The brief profile of Mr. Ravinatha is annexed with this disclosure.

The details required to be disclosed under the SEBI Listing Regulations read with SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 on the captioned subject is annexed herewith.

This is for your information and record.

Thanking you.

Yours faithfully,
For **Cohance Lifesciences Limited**
(Formerly, Suven Pharmaceuticals Limited)

Kundan Kumar Jha
Company Secretary, Compliance Officer and Head-Legal

Encl: as above



Disclosure of information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

1	Name of the person	Mr. Gunjan Singh	Mr. Amrit Singh	Mr. Ravinatha Shetty
2	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment of Mr. Gunjan Singh, Business Head – API plus, as Senior Management Personnel of the Company, with effect from December 5, 2025. The brief profile of Mr. Gunjan is annexed with this disclosure.	Appointment of Mr. Amrit Singh, Head – Specialty Chemicals, as Senior Management Personnel of the Company, with effect from December 5, 2025. The brief profile of Mr. Amrit is annexed with this disclosure.	Appointment of Mr. Ravinatha Shetty, Platform Chief Operating Officer, as Senior Management Personnel of the Company, with effect from December 5, 2025. The brief profile of Mr. Ravinatha is annexed with this disclosure.
3	Date of appointment/ re-appointment/ cessation (as applicable) & term of appointment/ re-appointment	Mr. Gunjan Singh, Business Head – API plus, has been appointed as Senior Management Personnel of the Company, with effect from December 5, 2025.	Mr. Amrit Singh, Head – Specialty Chemicals, has been appointed as Senior Management Personnel of the Company, with effect from December 5, 2025.	Mr. Ravinatha Shetty, Platform Chief Operating Officer, has been appointed as Senior Management Personnel of the Company, with effect from December 5, 2025.
4	Brief Profile (in case of appointment)	Brief profile is annexed	Brief profile is annexed	Brief profile is annexed
5	Disclosure of relationship between directors (in case of appointment)	Not applicable	Not applicable	Not applicable

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana, India.
Tel: +91 40 2354 9414 / 3311

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala MIDC, Mumbai - 400093, Maharashtra, India.
Tel: +91 22 6153 9999

CIN: L24299MH2018PLC422236 | Website: www.suvenpharm.com | Company Email: info@suvenpharm.com



Profile of Mr. Gunjan Singh



Mr. Gunjan Singh joined the Company in May 2025 as Business Head – API plus. He is responsible for API and formulations portfolio. In this role, he drives strategic growth, customer alignment, and operational excellence across the platform.

With over two decades of experience spanning APIs, Formulations, and CDMO, Gunjan brings deep expertise in business strategy, portfolio management, business development, and P&L leadership. Before joining Cohance, he was part of Dr. Reddy's PSAI (Pharmaceutical Services and Ingredients) business, where he managed operations across North America, South America, and Europe, and headed Product Management and Strategy. His previous leadership roles include CEO of Wanbury, SBU Head for API Business at Jubilant Pharmova, and Head of Sales & Marketing at Piramal Pharma for their Generic API, Nutrition, and ROW CDMO business. Earlier in his career, Gunjan worked as a Strategy Consultant with Accenture.

Gunjan is an alumnus of IIT Delhi and SP Jain, Mumbai.

Profile of Mr. Amrit Singh



Mr. Amrit Singh joined the Company in February, 2025 as Head – Specialty Chemicals. At Cohance Lifesciences, he is responsible for driving growth and scaling the Specialty Chemicals business unit.

He brings over 20 years of leadership experience across leading organizations such as Navin Fluorine, SRF Ltd., UPL, and Unilever. In his most recent role as CEO of the Specialty Chemicals Business Unit at Navin Fluorine, he spearheaded capex-driven initiatives that delivered multifold growth in P&L and fostered strategic collaborations with innovators in AgChem and Performance Chemicals.

Mr. Amrit holds a B. Tech. in Chemical Engineering (Gold Medalist) and an Executive MBA from IIM Calcutta. His accomplishments include being recognized as a High Potential Individual at SRF and awarded the Best Debutant Award in 2013.

Profile of Mr. Ravinatha Shetty



Mr. Ravinatha Shetty joined the Company in November, 2025 as Platform Chief Operating Officer. Mr. Ravinatha is overseeing Supply Chain Management, EHS, Ops Excellence, and Corporate & Industrial Affairs functions. In this role, he works closely with leaders across the CDMO, API, and Specialty Chemicals divisions to drive synergy, alignment, and strategic progress. At Cohance Lifesciences, he is responsible for strengthening operational excellence and accelerating organizational growth.

With nearly 35 years of leadership experience across the pharmaceutical and specialty chemicals sectors, including Lupin, Watson Pharma, Zydus Cadila, Cipla, Dr. Reddy's, and Aurobindo Pharma, Ravinatha brings deep expertise in operations leadership, site management, and cross-functional excellence.

A Chemical Engineer with a degree in Strategic Management from IIM Kozhikode, Ravinatha combines strong technical depth with proven operational acumen.

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana, India.

Tel: +91 40 2354 9414 / 3311

CIN: L24299MH2018PLC422236 | Website: www.suvenpharm.com | Company Email: info@suvenpharm.com

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala MIDC, Mumbai - 400093, Maharashtra, India.

Tel: +91 22 6153 9999

